NCT00945802终止3 期
A Multi-Center, Randomized, Double-Masked Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Shire
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.
研究概览
简要总结
The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a clinical diagnosis of AOE in one or both ears, defined as a clinical score of at least 1 for edema (0-3 scale), 2 for overall inflammation (0-3 scale) and 1 for tenderness (absent=0, present=1).
- •Be at least 18 years of age at Visit 1 (Day 1, Screening/Baseline) of either sex and any race.
- •Provide written informed consent or parental assent.
- •Be willing and able to follow all instructions and attend all study visits
排除标准
- •All subjects must not:
- •Have known sensitivity to any component of the study medications
- •Have a current infection requiring systemic antimicrobial treatment
- •Have used topical or systemic pain meds on the same day as Screening/Baseline Visit 1 and for the duration of the study.
- •Take any systemic (within 30 days) or otic corticosteroids (within 1 days) prior to Screening/Baseline Visit 1
- •Current use of topical or systemic non-steroidal or other anti-inflammatory drugs.
- •Use any topical otic treatment with alcohol, vinegar, hydrogen peroxide or other astringent medication during the course of the study or on the same day as Screening/Baseline Visit 1
- •Have taken any antibiotics within 3 days prior to Visit 1
- •Have signs and symptoms of AOE for > 4 weeks at Screening/Baseline Visit 1
- •Have a non-intact or perforated tympanic membrane in the enrolled ear
- •Have a clinical diagnosis of chronic suppurative otitis media, acute otitis media or acute otorrhea in patients with tympanostomy tubes
- •Have a clinical diagnosis of malignant otitis externa
- •Have overt fungal AOE
- •Have a viral infection of the pinna or tympanic membrane (i.e herpes zoster)
- •Have congenital abnormalities of the external auditory canal in the enrolled ear(s)
- •Have obstructive bony exostoses in the enrolled ear(s)
- •Have mastoid or other suppurative, non-infectious ear disorders (e.g, cholesteatoma)
- •Have malignant tumors of the external auditory canal
- •Have a history of otologic surgery. Surgery performed more than 1 year prior to Screening/Baseline Visit 1and limited to the tympanic membrane is allowed
- •Have seborrheic dermatitis of the external auditory canal
- •Have a current or prior history of immunosuppressive disorders
- •Have acute or chronic renal insufficiency, hepatitis or diabetes mellitus
- •Be pregnant, nursing or planning a pregnancy.
研究组 & 干预措施
FST-201 (dexamethasone 0.1%) Otic Suspension
Experimental
干预措施: FST-201 (dexamethasone 0.1%) Otic Suspension (Drug)
ciprofloxacin 0.3%, dexamethasone 0.1%
Active Comparator
干预措施: ciprofloxacin 0.3%, dexamethasone 0.1% (Drug)
结局指标
主要结局
Overall clinical cure as defined by absence of the signs and symptoms of AOE including ear inflammation, edema, tenderness and otic discharge.
时间窗: 1 year
次要结局
- Microbiological resolution defined as elimination of pre-treatment pathogenic bacteria.(1 year)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
FST-201 in the Treatment of Acute Otitis ExternaAcute Otitis ExternaNCT00961675Shire70
终止
2 期
FST-100 Ophthalmic Suspension in Acute Adenoviral ConjunctivitisAcute Adenoviral ConjunctivitisNCT00941486Shire30
已完成
3 期
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant RecipientsRenal TransplantationNCT00239785Novartis Pharmaceuticals684
已完成
3 期
A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaUnresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaNCT04187352CStone Pharmaceuticals540
已完成
2 期
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOXColorectal CancerNCT00384176AstraZeneca1,814